#project cbd

[scott-gelbard]

Project CBD Newsletter: CBD for Neuroinflammation Alzheimers Neuropathic Pain Oral Health Acne Medical Cannabis Sick Leave and DEA Rescheduling Update

Project CBD Newsletter: CBD for Neuroinflammation, Alzheimer’s, Neuropathic Pain, Oral Health, Acne, Medical Cannabis Sick Leave, and DEA Rescheduling Update https://ift.tt/jRcF6On This week’s plant medicine newsletter covers CBD’s potential for neuroinflammation and Alzheimer’s disease, new research on CBD for chemotherapy-induced pain, oral health, and acne, plus updates on medical cannabis in the workplace and the DEA’s rescheduling proceedings. Noteworthy Read Can CBD Play a Role in Treating Alzheimer’s Disease? (Dr. Andrew Weil) Dr. Andrew Weil reviews emerging evidence that CBD may have relevance for Alzheimer’s disease, particularly through its effects on neuroinflammation and brain immune activity. The piece looks at CBD within the broader conversation about how cannabinoids may help protect the aging brain and support new approaches to neurodegenerative disease. Read the full article Note: Project CBD interviewed Dr. Weil in 2023 on cannabis and integrative medicine. Read the interview here. View more in CBD More Noteworthy Reading Medical Cannabis Cuts Employee Sick Days (Inc.) Inc. reports on research linking medical cannabis access to fewer health-related work absences, with employee sick days falling by about 7% in states with medical cannabis laws. The findings suggest legal access may help some workers better manage chronic symptoms and remain active in the workforce. Read more View more in CBD US Tobacco Giant Is Behind Planned Takeover of Biggest Licensed Dutch Cannabis Grower (Cannabis Law Report) Cannabis Law Report highlights a planned takeover involving the Netherlands’ largest licensed cannabis grower and a major U.S. tobacco company. The story underscores the growing interest of legacy tobacco firms in regulated cannabis markets as medical and adult-use systems mature. Read more View more in CBD DEA Argues in Favor of Moving Cannabis to Schedule III (Ganjapreneur) The DEA has spent years dragging its feet on cannabis rescheduling, and now it’s standing in its own courtroom, calling its own witnesses, and arguing that the rule should actually go into effect. Read more View more in THC Research Round-Up CBD Attenuates Chemo-Induced Peripheral Neuropathic Pain (PubMed) New research suggests CBD may reduce chemotherapy-induced peripheral neuropathic pain, a common and difficult side effect of cancer treatment. The study connects CBD’s pain-modulating effects with endocannabinoid and lipid signaling pathways, adding to interest in cannabinoids as supportive tools in oncology care. Read more View more in Endocannabinoid System CBD Mouthwash Effective Without Damaging Enamel (Marijuana Herald) A new study found that a low-concentration CBD mouthwash helped control dental biofilm without damaging enamel properties. The findings point to CBD’s potential in oral health formulations, especially as researchers explore alternatives to conventional antimicrobial ingredients. Read more View more in CBD CBD-Rich Cannabis Extracts and CBD Isolate for Acne (Molecules) A new review examines CBD-rich cannabis extracts and isolated CBD as potential tools for managing inflammatory acne. The authors highlight CBD’s anti-inflammatory and sebum-regulating properties, connecting cannabinoid science with a growing interest in plant-derived dermatology. Read more View more in CBD A heartfelt thank you to all of the CBD brands whose generous support allows Project CBD to shine a light on the latest plant medicine research and bring these stories to our readers each week. The post Project CBD Newsletter: CBD for Neuroinflammation, Alzheimer’s, Neuropathic Pain, Oral Health, Acne, Medical Cannabis Sick Leave, and DEA Rescheduling Update appeared first on Project CBD. via Project CBD https://projectcbd.org July 3, 2026 at 12:36PM

[scott-gelbard]

Project CBD Newsletter: CBD for Digital Era Fatigue Psychedelics Research Risks and Methods Whole-Mushroom Psilocybin and the Endocannabinoid Systems Role in Muscle Health

Project CBD Newsletter: CBD for Digital Era Fatigue, Psychedelics Research Risks and Methods, Whole-Mushroom Psilocybin, and the Endocannabinoid System’s Role in Muscle Health https://ift.tt/zfKLboW This week’s newsletter covers CBD’s potential for addressing digital era fatigue, critical perspectives on psychedelic research and clinical overreach, the case for whole-mushroom psilocybin studies, and new insights into the endocannabinoid system’s role in skeletal muscle health. Noteworthy Read CBD May Help Address “Digital Era Fatigue” (The Marijuana Herald) A new review suggests CBD may have potential for addressing “digital era fatigue,” a proposed syndrome linked to excessive screen time, cognitive tiredness, mood disruption, sleep problems, and stress. The authors point to CBD’s effects on inflammation, oxidative stress, serotonin signaling, and sleep regulation as evidence of its therapeutic utility for these types of issues. Read more View more in CBD More Noteworthy Reading When Do Psychedelics Go Too Far? (Medium) Andrew Weisse examines the cultural and clinical risks that can emerge when psychedelic use is framed as a universal solution or pushed beyond appropriate boundaries. In this article, he raises questions about overuse, weak screening, commercialization, spiritual bypassing, and the need for clearer norms around when psychedelic experiences may do more harm than good. Read more View more in Psychedelics Common Problems in Psychedelic Science (Sage Journals) This review outlines recurring issues in psychedelic research, including small sample sizes, weak blinding, inflated effect sizes, expectancy effects, and media hype. The paper is a useful reminder that enthusiasm around psychedelics needs to be matched with stronger methods, transparent reporting, and more careful claims about clinical promise. Read more View more in Psychedelics Time to Embrace the Whole: Magic Mushrooms Instead of Single-Molecule Psilocybin in Research and Therapy (Natural Products Research) This paper argues that psychedelic research should pay more attention to whole psilocybin-containing mushrooms rather than focusing almost exclusively on isolated psilocybin. The authors suggest that other mushroom compounds may influence therapeutic effects, safety, or tolerability, though controlled studies are needed to test whether whole-mushroom preparations offer meaningful advantages. Read more View more in Psychedelics Research Round-Up Endocannabinoid System and Skeletal Muscle Health: Insights From CBD (Molecular Metabolism) A new review examines how the endocannabinoid system may influence skeletal muscle health, including metabolism, inflammation, mitochondrial function, and muscle repair. The paper uses CBD as a framework for exploring cannabinoid-related pathways in muscle biology, looking at research that connects cannabinoids with metabolic and musculoskeletal health. Read more View more in Endocannabinoid System A heartfelt thank you to all of the CBD brands whose generous support allows Project CBD to shine a light on the latest plant medicine research and bring these important stories to our community. The post Project CBD Newsletter: CBD for Digital Era Fatigue, Psychedelics Research Risks and Methods, Whole-Mushroom Psilocybin, and the Endocannabinoid System’s Role in Muscle Health appeared first on Project CBD. via Project CBD https://projectcbd.org June 19, 2026 at 01:58PM

[scott-gelbard]

Project CBD Newsletter: CBD and Alzheimers Brain Inflammation Psilocybin Research Cannabis for Pain and Drug Policy Analysis

Project CBD Newsletter: CBD and Alzheimer’s Brain Inflammation, Psilocybin Research, Cannabis for Pain, and Drug Policy Analysis https://ift.tt/8SxGk29 This week’s newsletter covers CBD’s potential to reduce Alzheimer’s-related brain inflammation, psilocybin’s promise for pain relief and neurological conditions, cannabis as an alternative to opioids for chronic pain, and critical perspectives on AI safety and U.S. drug policy. Noteworthy Read CBD Shows Early Promise for Reducing Brain Inflammation in Alzheimer’s Model (Discover Magazine) New research in a mouse model of Alzheimer’s disease suggests CBD may reduce chemical markers associated with brain inflammation. The findings add to growing interest in cannabinoids and neuroinflammation, and highlight the importance of further research to explore efficacy in humans. Read the full article View more in CBD More Noteworthy Reading Parents Sue OpenAI After Their Son Dies of a Drug Overdose (CBS News) CBS News reports on a lawsuit filed by the parents of a 19-year-old who died of a drug overdose after allegedly using ChatGPT to seek drug-related advice. The case raises broader questions about AI safety, health misinformation, platform accountability, and how emerging technologies should handle conversations involving substance use and medical risk. Read more View more in Drug Interactions Trump’s ‘Narco-Terrorism’ War in Latin America Is More About Fighting Leftists Than Drug Runners (The Conversation) This analysis argues that the Trump administration’s framing of Latin American drug cartels as “narco-terrorist” threats echoes earlier U.S. interventions that blurred drug policy, national security, and anti-leftist foreign policy goals. Considering drug-war rhetoric within a longer history of militarized U.S. policy in the region, it raises questions about whether anti-drug campaigns are again being used to justify broader geopolitical aims. Read more View more in CBD Medical Cannabis Helps People With Hypermobility Disorders Experience Less Pain, Consume Fewer Opioids (NORML) A new study found that patients with hypermobility-related disorders reported reduced pain and lower opioid use after beginning medical cannabis treatment. The results support further investigation of cannabis-based therapies for complex chronic pain conditions, especially where conventional medications provide incomplete relief or carry significant side effects. Read more View more in CBD Research Round-Up Case Report: High-Dose Psilocybin-Containing Mushroom Improves Advanced Alzheimer’s Disease (Frontiers in Neuroscience) A case report describes temporary functional improvements in an older woman with advanced Alzheimer’s disease after supervised administration of high-dose psilocybin-containing mushrooms. The report is striking though limited: it involves a single patient and does not show disease reversal, but it makes for a strong argument in support of future controlled research. Read more View more in Psychedelics Magic Mushroom Compound Enhances Nerve Pain Medication (PsyPost) New mouse research suggests psilocybin may provide lasting relief from neuropathic pain and enhance the effects of gabapentin, a commonly prescribed nerve pain medication. The findings point to a possible future role for psychedelics in chronic pain research, but the work remains preclinical and does not establish that psilocybin-gabapentin combinations are safe or effective in humans. Psychedelics A heartfelt thank you to all of the CBD brands whose generous support powers Project CBD’s commitment to bringing you the latest in plant medicine research and journalism — we couldn’t do this work without you. The post Project CBD Newsletter: CBD and Alzheimer’s Brain Inflammation, Psilocybin Research, Cannabis for Pain, and Drug Policy Analysis appeared first on Project CBD. via Project CBD https://projectcbd.org June 12, 2026 at 12:42PM

[freedomroad420]

Recent studies indicate that CBD influences the expression of some genes by directly activating PPAR-gamma, a non-cannabinoid receptor situated on the cell’s nucleus. CBD’s ability to activate PPAR-gamma has promising therapeutic implications, particularly with respect to cancer and metabolic disorders.

Ever wondered how CBD’s can help with SO many ailments? 

[hightimesmag]

“Everyday we get contacted by people asking, ‘Where can I get CBD? I just want CBD, the medical part, not the recreational part,’” Lee says, “as if THC is just recreational and not medical. And we have to disabuse people of this line of thought, because a CBD-dominant remedy like Charlotte’s Web can, in some cases, produce near miraculous results, but we know quite well, from the families that are involved with Charlotte’s Web, that only about 10 or 15 percent get that result. Most of the families are finding they need to have more THC, or more THC-A (THC acid), which is the unheated form of THC and which, as it turns out, is not psychoactive. So it’s clear that CBD and THC are involved in a synergistic relationship, they potentiate each other’s effect. Some people have a hard time tolerating THC. In that case, they might start on a product like Charlotte’s Web that’s much more dominant in CBD than THC, and then they could slowly increase the amount of THC to a comfortable level. And there’s hard science behind this, there have been studies that show, for example, that THC has very powerful anti-tumoral properties, animal studies show that THC will shrink tumors, but when combined with CBD, THC has a more potent anti-tumoral effect. So it’s very clear that it’s not just the individual compounds in the plant that are important, but the plant itself.”

Martin A. Lee, founder of Project CBD

Read "Behind the CBD Gold Rush" on HighTimes.com

[h4x0r3d]